Monte Rosa Therapeutics, Inc. (GLUE) analyst actions
Rating and price-target actions on GLUE in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the GLUE overview →
2 measured GLUE analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391) | Press release | +0.22% | +5.31% | |
| Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1ß Pathway Inhibitor | Press release | +0.47% | -2.35% |
Keep exploring
More GLUE: earnings → · SEC filings → · GLUE overview →